논란의 여지가 있는 AI 회사가 영국에서 확장함에 따라 뉴욕시 병원은 Palantir를 중단했습니다.
hackernews
|
|
🔬 연구
#ai 논란
#palantir
#review
#계약 해지
#뉴욕시 병원
#데이터 분석
원문 출처: hackernews · Genesis Park에서 요약 및 분석
요약
미국 최대 뮤니시펄 공공 의료 시스템인 뉴욕시 보건병원은 2023년 11월부터 팔란티어에 약 400만 달러를 지불했으나, 오는 10월 계약이 만료되면 갱신하지 않고 자체 개발 시스템으로 전환한다고 밝혔습니다. 해당 계약은 환자 데이터를 활용해 의료 수익을 최적화하는 단기적인 성격이었으나, 이민세단(ICE) 등과의 정보 공 가능성에 대한 우려가 제기되었습니다. 한편, 팔란티어는 뉴욕과의 계약 종료 소식과 맞물려 영국 보건 서비스(NHS)와의 3억 3000만 파운드 규모 계약 및 금융 당국과의 협력에서도 데이터 프라이버시 우려와 강한 반대에 직면해 있습니다.
본문
New York City’s public hospital system announced that it would not be renewing its contract with Palantir as controversy mounts in the UK over the data analytics and AI firm’s government contract. The president of the US’s largest municipal public healthcare system, Dr Mitchell Katz, testified last week before the New York city council that the agreement with Palantir would expire in October. He said at the hearing that the contract, which focused on recovering money for insurance claims, was always meant to be short-term, and that there was an “absolute firewall” preventing Palantir from sharing information with US Immigration and Customs Enforcement. He said that the agency had “not had any incidents”. The contract and related payment documents shared with the Guardian by the American Friends Service Committee and first reported by the Intercept, show that NYC Health + Hospitals has paid Palantir nearly $4m since November 2023. The contract noted that Palantir would be able to review notes about patients’ health and help the hospital claim more money in public benefits through programs such as Medicaid. It also includes a line stating that with permission from the city agency, Palantir can “de-identify” patients’ protected health information and use it for “purposes other than research”. NYC Health + Hospitals said in an email to the Guardian that it will be transitioning to systems that were made entirely in-house, and there will be no data shared with Palantir or use of the company’s applications after the contract expires. “NYC Health + Hospitals’ use of Palantir technology is strictly limited to revenue cycle optimization, helping the public healthcare system close gaps between services delivered and charges captured, protect critical revenue, and reduce avoidable denials,” the agency said in an emailed statement. A Palantir spokesperson said in a statement: “Palantir, as a software company, does not own or have any rights to customer data – and each customer environment is individually protected against unauthorized access or misuse via robust security controls which can be fully administered and audited by the customer.” Palantir presence grows in the UK As New York City’s hospital system prepares to part ways with Palantir, the company is facing similar scrutiny over privacy issues in its £330m agreement with the UK’s National Health Service (NHS). Health officials in the UK are concerned that the controversy surrounding Palantir may stop the nationwide rollout of the company’s data system, even though Keir Starmer is trying to speed up deployment. As of last summer, not even half of the country’s health authorities had started using Palantir’s technology amid concerns from the community and doctors. A 12 March briefing by Medact, a health justice charity, said Palantir’s software could enable “data-driven state abuses of power”, including US-style ICE raids. Palantir has denied that the data could be used in this way, noting that it would be illegal and a breach of contract. Palantir, which also contracts with the British government’s Ministry of Defence, is expanding its influence in the country – despite backlash from activists and some lawmakers. The Guardian revealed last week that Palantir is trying to gain access to sensitive national financial regulation data. The Financial Conduct Authority, a watchdog for thousands of financial bodies from banks to hedge funds, awarded Palantir a contract to investigate internal intelligence data to help root out financial crime. That has sparked outcry from some MPs, who have urged the government to halt this agreement. Liberal Democrats called on Monday for a government investigation into the contract. Starmer has dismissed suggestions that the UK has become “dangerously over-reliant” on American tech companies, including Palantir, but noted he preferred to have more domestic capability. Medact has raised privacy concerns in the UK about Palantir’s ability to access de-identified patient data. (De-identified data refers to data that has been stripped of characteristics that could indicate who an individual is, such as names and social security numbers.) In a 12 March briefing for health officials, Medact argued that the NHS’s data privacy protections are insufficient; NHS England has said that data is de-identified as it moves through its national software system, the NHS federated data platform (FDP). But Medact cited concerns that this data can be easily re-identified. An NHS spokesperson said in an emailed statement to the Guardian that the supplier of the FDP “was appointed in line with public contract regulations and must only operate under the instruction of the NHS, with all access to data remaining under NHS control and strict contractual obligations protecting confidentiality”. Data privacy concerns Data privacy experts interviewed by the Guardian said that there are risks in Palantir accessing New Yorkers’ de-identified data for purposes other
Genesis Park 편집팀이 AI를 활용하여 작성한 분석입니다. 원문은 출처 링크를 통해 확인할 수 있습니다.
공유